G1 Therapeutics, Inc. (GTHX)
- Previous Close
4.1000 - Open
4.1500 - Bid 4.2100 x 200
- Ask 4.2900 x 200
- Day's Range
4.1000 - 4.3200 - 52 Week Range
1.0800 - 5.0000 - Volume
117,594 - Avg. Volume
1,318,262 - Market Cap (intraday)
221.847M - Beta (5Y Monthly) 1.70
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9300 - Earnings Date May 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.50
G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
www.g1therapeutics.comRecent News: GTHX
Performance Overview: GTHX
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GTHX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GTHX
Valuation Measures
Market Cap
214.02M
Enterprise Value
187.76M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.57
Price/Book (mrq)
6.05
Enterprise Value/Revenue
2.28
Enterprise Value/EBITDA
-5.47
Financial Highlights
Profitability and Income Statement
Profit Margin
-58.13%
Return on Assets (ttm)
-15.96%
Return on Equity (ttm)
-92.13%
Revenue (ttm)
82.51M
Net Income Avi to Common (ttm)
-47.97M
Diluted EPS (ttm)
-0.9300
Balance Sheet and Cash Flow
Total Cash (mrq)
82.16M
Total Debt/Equity (mrq)
161.57%
Levered Free Cash Flow (ttm)
-19.99M